US › Healthcare

Exagen Inc (XGN)

US · Healthcare · Diagnostics & Research

$6.45+37.82%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$17.3M
Revenue YoY
+11.7%
Net profit
$-4.0M
Profit YoY
-5.7%
EPS
$-0.20
EPS estimate
$-0.25
Net margin
-22.9%

EPS came in at -0.20 against a street estimate of -0.25 — a beat of 20.0%.

Key statistics

Market cap
$113.1M
Forward P/E
0.0
P/B
7.58
Book value
$0.60
EPS (TTM)
$-0.90
52-week high
$12.23
52-week low
$2.59
50-day MA
$4.54
200-day MA
$5.26
Beta
2.03

Analyst view

Analysts rate Exagen Inc a strong buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $8.57.

Shareholding

Insiders
27.91%
Institutions
54.98%

Largest institutional holders

FundStake
Balyasny Asset Management LLC3.30%
Wexford Capital LP3.28%
Vanguard Group Inc3.27%
Acadian Asset Management LLC2.85%
Vanguard Capital Management, LLC2.81%
NANO CAP NEW MILLENNIUM GROWTH FUND L P2.42%
Silvercrest Asset Management Group LLC2.23%
Kennedy Capital Management Inc2.04%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Exagen Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.